Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Single-center, Phase II Study of Sintilimab, Peg-aspargase Plus Anlotinib "Sandwich"With Radiotherapy in Previously Untreated Stage I-II Extranodal NK/T Cell Lymphoma

NCT03936452 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT03936452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03936452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Single-center, Phase II Study of Sintilimab, Peg-aspargase Plus Anlotinib "Sandwich"With Radiotherapy in Previously Untreated Stage I-II Extranodal NK/T Cell Lymphoma
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Completed
Start date
April 28, 2019
Completion date
December 30, 2021
Enrollment
55 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anlotinib, early stage, natural killer/t-cell lymphoma, nasal and nasal-type, open, peg-aspargase, phase two, radiotherapy, sintilimab